The Asian Dengue Vaccine Advocacy (ADVA) is a scientific working group dedicated to dengue vaccine advocacy in Asia, with the aim of disseminating information and making recommendations on dengue vaccine introduction strategies in Asia.
Set up in 2011, ADVA’s mission is to identify opportunities and make practical recommendations for improving surveillance and laboratory capacity for dengue disease confirmation, including documenting and standardising existing systems and coverage, standardising case confirmation and diagnostics, selecting initial target groups for vaccination, addressing programme feasibility by improving existing infrastructure (cold chain, pharmacovigilance, vaccination compliance monitoring, and vaccine supply and distribution logistics), preparing and implementing a risk management plan, collaborating with other relevant dengue initiatives including V2V (vaccine to vaccination) and the Dengue Vaccine Initiative.
The value of the ADVA initiative lies in its collaborative approach to sharing surveillance data and relevant information, which are important in ensuring the success of the Dengue disease prevention through vaccination.
ADVA also reinforces the importance of a united front against dengue and presents a collaborative model for joint effort in the region focused on the prevention of the disease through the introduction and implementation of dengue vaccination.
The group has formulated recommendations with an ultimate aim of translating the science of dengue vaccination into messages for policy makers, general public and health care workers.
